Spero Announces Positive Interim Phase 1 SAD/MAD Results for SPR994

Clinical data demonstrate SPR994 to be well tolerated at single and multiple ascending doses Data support selection of SPR994 300 mg TID dose for use in a pivotal Phase 3 clinical trial, planned to initiate around year-end 2018 CAMBRIDGE, Mass. , July 09, 2018 (GLOBE NEWSWIRE) — Spero


Leave a Reply

Your email address will not be published.